MX2011014024A - Acido trans-4-[[(5s)-5-[[[3,5-bis (trifluorometil)fenil]metil] (2-metil-2h-tetrazol-5-il)amino]-2,3,4,5-tetrahidro-7,9-dimetil-1 h-1-benzazepin-1-il]metil]-ciclohexancarboxilico. - Google Patents

Acido trans-4-[[(5s)-5-[[[3,5-bis (trifluorometil)fenil]metil] (2-metil-2h-tetrazol-5-il)amino]-2,3,4,5-tetrahidro-7,9-dimetil-1 h-1-benzazepin-1-il]metil]-ciclohexancarboxilico.

Info

Publication number
MX2011014024A
MX2011014024A MX2011014024A MX2011014024A MX2011014024A MX 2011014024 A MX2011014024 A MX 2011014024A MX 2011014024 A MX2011014024 A MX 2011014024A MX 2011014024 A MX2011014024 A MX 2011014024A MX 2011014024 A MX2011014024 A MX 2011014024A
Authority
MX
Mexico
Prior art keywords
methyl
benzazepin
tetrazol
tetrahydro
trifluoromethyl
Prior art date
Application number
MX2011014024A
Other languages
English (en)
Spanish (es)
Inventor
David Michael Remick
Steven Wayne Pedersen
Scott Alan Frank
Xinchao Chen
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42352717&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2011014024(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX2011014024A publication Critical patent/MX2011014024A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX2011014024A 2009-06-30 2010-06-28 Acido trans-4-[[(5s)-5-[[[3,5-bis (trifluorometil)fenil]metil] (2-metil-2h-tetrazol-5-il)amino]-2,3,4,5-tetrahidro-7,9-dimetil-1 h-1-benzazepin-1-il]metil]-ciclohexancarboxilico. MX2011014024A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22170809P 2009-06-30 2009-06-30
PCT/US2010/040125 WO2011002696A1 (en) 2009-06-30 2010-06-28 Trans-4-[[(5s)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl] (2-methyl-2h-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1h-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acid

Publications (1)

Publication Number Publication Date
MX2011014024A true MX2011014024A (es) 2012-04-20

Family

ID=42352717

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2011014024A MX2011014024A (es) 2009-06-30 2010-06-28 Acido trans-4-[[(5s)-5-[[[3,5-bis (trifluorometil)fenil]metil] (2-metil-2h-tetrazol-5-il)amino]-2,3,4,5-tetrahidro-7,9-dimetil-1 h-1-benzazepin-1-il]metil]-ciclohexancarboxilico.

Country Status (37)

Country Link
US (2) US8329688B2 (enExample)
EP (1) EP2448933B1 (enExample)
JP (1) JP5689875B2 (enExample)
KR (1) KR101404893B1 (enExample)
CN (1) CN102639528B (enExample)
AR (1) AR077208A1 (enExample)
AU (1) AU2010266537B2 (enExample)
BR (1) BRPI1011931A2 (enExample)
CA (1) CA2764425C (enExample)
CL (1) CL2011003263A1 (enExample)
CO (1) CO6480934A2 (enExample)
CR (1) CR20110669A (enExample)
DK (1) DK2448933T3 (enExample)
DO (1) DOP2011000405A (enExample)
EA (1) EA020600B1 (enExample)
EC (1) ECSP11011551A (enExample)
ES (1) ES2435293T3 (enExample)
GT (1) GT201100321A (enExample)
HR (1) HRP20130950T1 (enExample)
IL (1) IL216655A (enExample)
JO (1) JO2867B1 (enExample)
MA (1) MA33385B1 (enExample)
ME (1) ME01606B (enExample)
MX (1) MX2011014024A (enExample)
MY (1) MY157121A (enExample)
NZ (1) NZ596820A (enExample)
PE (1) PE20120538A1 (enExample)
PL (1) PL2448933T3 (enExample)
PT (1) PT2448933E (enExample)
RS (1) RS52988B (enExample)
SG (1) SG177413A1 (enExample)
SI (1) SI2448933T1 (enExample)
TN (1) TN2011000638A1 (enExample)
TW (1) TWI450896B (enExample)
UA (1) UA109409C2 (enExample)
WO (1) WO2011002696A1 (enExample)
ZA (1) ZA201108707B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA200700119A1 (ru) * 2004-06-24 2007-10-26 Эли Лилли Энд Компани Соединения и способы лечения дислипидемии
TWI450896B (zh) * 2009-06-30 2014-09-01 Lilly Co Eli 反式－４－〔〔（５ｓ）－５－〔〔〔３，５－雙（三氟甲基）苯基〕甲基〕（２－甲基－２ｈ－四唑－５－基）胺基〕－２，３，４，５－四氫－７，９－二甲基－１ｈ－１－苯并氮呯－１－基〕甲基〕－環己基羧酸
RU2609200C2 (ru) * 2011-07-08 2017-01-30 Новартис Аг Способ лечения атеросклероза у субъектов с высоким уровнем триглицеридов
WO2014012401A1 (zh) * 2012-07-16 2014-01-23 上海恒瑞医药有限公司 苯并七元杂环类衍生物、其制备方法及其在医药上的应用
DK2943474T3 (en) 2013-01-31 2017-08-21 Chong Kun Dang Pharmaceutical Corp BIARYL- OR HETEROCYCLIC BIARYL-SUBSTITUTED CYCLOHEXE DERIVATE COMPOUNDS AS CETP INHIBITORS
CN105017085B (zh) * 2014-04-28 2018-06-29 中国科学院上海药物研究所 一类kcnq钾通道激动剂、其制备方法和用途
JP6854752B2 (ja) 2014-07-30 2021-04-07 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ Ｈｄｌ上昇剤又はｈｄｌ模倣剤を用いた治療に対する応答性を予測するための遺伝マーカー
TWI691331B (zh) 2014-09-26 2020-04-21 日商興和股份有限公司 脂質異常症治療劑
CN108456213B (zh) * 2017-02-22 2021-01-15 浙江九洲药业股份有限公司 一种3-氟-4-羟基环己烷羧酸酯的制备方法
WO2025093129A1 (en) 2023-11-01 2025-05-08 Newamsterdam Pharma B.V. Treatment and prevention of age-related macular degeneration using a cetp inhibitor

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4948639B1 (enExample) 1970-12-15 1974-12-23
GT199900147A (es) 1998-09-17 1999-09-06 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas.
US6147089A (en) 1998-09-17 2000-11-14 Pfizer Inc. Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
CO5271716A1 (es) 1999-11-30 2003-04-30 Pfizer Prod Inc Cristales de 4- carboxamino 1,2,3,4-tetrahidroquinolina 2- sustituida
HN2000000203A (es) 1999-11-30 2001-06-13 Pfizer Prod Inc Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas 4-carboxiamino-2- sustituidas.
CZ20032898A3 (cs) 2001-04-30 2004-07-14 Pfizer Products Inc. Způsob výroby inhibitorů CETP
NZ532494A (en) 2002-08-30 2006-03-31 Japan Tobacco Inc Dibenzylamine compound and medicinal use thereof
MXPA05003456A (es) 2002-10-04 2005-07-05 Millennium Pharm Inc Antagonistas del receptor de pgd2 para el tratamiento de enfermedades inflamatorias.
JP2006523218A (ja) 2003-03-04 2006-10-12 高砂香料工業株式会社 光学活性アミン類の製造方法
US20040204450A1 (en) * 2003-03-28 2004-10-14 Pfizer Inc Quinoline and quinoxaline compounds
SI1670768T1 (sl) * 2003-10-08 2010-01-29 Lilly Co Eli Spojine in metode za zdravljenje dislipidemije
PT1732933E (pt) 2004-03-26 2008-10-20 Lilly Co Eli Compostos para o tratamento da dislipidémia
EA200700119A1 (ru) 2004-06-24 2007-10-26 Эли Лилли Энд Компани Соединения и способы лечения дислипидемии
CN1972927A (zh) * 2004-06-24 2007-05-30 伊莱利利公司 用于治疗血脂障碍的化合物和方法
US7700774B2 (en) 2004-12-20 2010-04-20 Dr. Reddy's Laboratories Ltd. Heterocyclic compounds and their pharmaceutical compositions
TWI450896B (zh) * 2009-06-30 2014-09-01 Lilly Co Eli 反式－４－〔〔（５ｓ）－５－〔〔〔３，５－雙（三氟甲基）苯基〕甲基〕（２－甲基－２ｈ－四唑－５－基）胺基〕－２，３，４，５－四氫－７，９－二甲基－１ｈ－１－苯并氮呯－１－基〕甲基〕－環己基羧酸

Also Published As

Publication number Publication date
ME01606B (me) 2014-09-20
RS52988B (sr) 2014-02-28
US8329688B2 (en) 2012-12-11
SI2448933T1 (sl) 2013-11-29
SG177413A1 (en) 2012-02-28
KR20120027426A (ko) 2012-03-21
KR101404893B1 (ko) 2014-06-20
AR077208A1 (es) 2011-08-10
US20100331309A1 (en) 2010-12-30
EA201270099A1 (ru) 2012-05-30
CO6480934A2 (es) 2012-07-16
US8299060B2 (en) 2012-10-30
EP2448933B1 (en) 2013-08-28
EP2448933A1 (en) 2012-05-09
NZ596820A (en) 2013-07-26
MY157121A (en) 2016-05-13
AU2010266537B2 (en) 2013-04-18
CA2764425A1 (en) 2011-01-06
IL216655A (en) 2015-02-26
AU2010266537A1 (en) 2012-02-02
CL2011003263A1 (es) 2012-07-27
JP5689875B2 (ja) 2015-03-25
CR20110669A (es) 2012-03-16
BRPI1011931A2 (pt) 2016-04-19
TWI450896B (zh) 2014-09-01
PE20120538A1 (es) 2012-05-09
IL216655A0 (en) 2012-02-29
JO2867B1 (en) 2015-03-15
ZA201108707B (en) 2013-05-29
HRP20130950T1 (hr) 2013-11-22
CA2764425C (en) 2015-01-06
WO2011002696A1 (en) 2011-01-06
PL2448933T3 (pl) 2014-01-31
UA109409C2 (ru) 2015-08-25
TW201113275A (en) 2011-04-16
PT2448933E (pt) 2013-10-29
DK2448933T3 (da) 2013-10-07
DOP2011000405A (es) 2012-01-15
JP2012532106A (ja) 2012-12-13
MA33385B1 (fr) 2012-06-01
ECSP11011551A (es) 2012-01-31
US20120058990A1 (en) 2012-03-08
CN102639528B (zh) 2014-07-16
CN102639528A (zh) 2012-08-15
ES2435293T3 (es) 2013-12-18
EA020600B1 (ru) 2014-12-30
TN2011000638A1 (en) 2013-05-24
GT201100321A (es) 2012-11-15

Similar Documents

Publication Publication Date Title
TN2011000638A1 (en) Trans-4-[[(5s)-5-[[[3,5-bis(trifluoromethyl)phenyl]methyl] (2-methyl-2h-tetrazol-5-yl)amino]-2,3,4,5-tetrahydro-7,9-dimethyl-1h-1-benzazepin-1-yl]methyl]-cyclohexanecarboxylic acid
MX2010006799A (es) Benzofuropirimidinonas como inhibidores de la proteina cinasa.
MY153985A (en) Aminotriazole derivatives as alx agonists
MY162940A (en) Quinoline derivative-containing pharmaceutical composition
IL223002A0 (en) Crystalline form of 4- [5 - [3 -chloro-5 - (trifluoromethyl) phenyl] -4, 5 - dihydro - 5 - (trifluoromethyl) -3 - isoxazolyl] -n- [2-0x0-2- [ ( 2, 2, 2 - trifluoroethyl) amino] ethyl] -1- naphthalenecarboxamide
WO2010132999A8 (en) Methyl sulfanyl pyrmidmes useful as antiinflammatories, analgesics, and antiepileptics
WO2012007869A3 (en) N- sulfonylbenzamides as inhibitors of voltage - gated sodium channels
UA115320C2 (uk) Інгібітори кінази
MX342440B (es) Derivados fluorados de aminotriazol.
UA105788C2 (uk) Натрієва сіль 5-циклопропіл-2-{[2-(2,6-дифторфеніл)піримідин-5-іл]аміно}бензойної кислоти як інгібітори dhodh
PH12012500992A1 (en) Compound, certain novel forms thereof, pharmaceutical compositions thereof and methods for preparation and use
EA201101210A1 (ru) 5-(2-{[6-(2,2-дифтор-2-фенилэтокси)гексил]амино}-1-гидроксиэтил)-8-гидроксихинолин-2(1h)-oh для лечения легочной функции
PH12012501974A1 (en) Novel hypoglycemic compounds
WO2006051314A8 (en) Guanidine derivatives as inhibitors of ddah
CY1114514T1 (el) Τrανs-4-[[(5s)-5-[[[3,5-δις(τριφθορομεθυλ)φαινυλ]μεθυλ](2-μεθυλ-2η-τετραζολ-5-υλ)αμινο]-2,3,4,5-τετραϋδρο-7,9-διμεθυλ-1η-1-βενζαζεπιν-1 -υλ]μεθυλ]-κυκλοεξανο-καρβοξυλικο οξυ
AR083322A1 (es) Compuesto (3-{[{4-[4-amino-2-(etoximetil)-1h-imidazol[4,5-c]quinolin-1-il]butil}(n,n-dietilglicil)amino]metil}fenil)acetato de metilo
SI2125761T1 (sl) Nov postopek za sintezo pramipeksola in njegovih farmacevtsko sprejemljivih soli
NZ624621A (en) Manufacturing process for pyrimidine derivatives
HK1161879A (en) Pharmaceutically acceptable salts of pyrrolo-nitrogenous heterocyclic derivatives, preparation method and medical use thereof
HK1144070A1 (zh) 肽脫甲酰基酶抑制劑

Legal Events

Date Code Title Description
FG Grant or registration